Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2525]

ASCO 2020: Immunotherapy following chemotherapy offers extended survival to patients with advanced urothelial cancer

ASCO 2020: Immunotherapy following chemotherapy offers extended survival to patients with advanced urothelial...

ASCO 2020: Early data show cancer progression associated with increased risk of death in patients with COVID-19

ASCO 2020: Early data show cancer progression associated with increased risk of death in patients with COVID-19

Potentially treatable genetic mutations revealed in subset of prostate cancer patients

Potentially treatable genetic mutations revealed in subset of prostate cancer patients

FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer

FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer

Childhood obesity raises bladder cancer risk, study looking at 315,000 children suggests

Childhood obesity raises bladder cancer risk, study looking at 315,000 children suggests

New LAT1 inhibitor can boost cancer treatment

New LAT1 inhibitor can boost cancer treatment

FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer

FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer

Researchers develop model to predict prostate cancer aggressiveness

Researchers develop model to predict prostate cancer aggressiveness

Combination of chemo and immunotherapy is shown to work against metastatic bladder cancer

Combination of chemo and immunotherapy is shown to work against metastatic bladder cancer

ASCO 2020: Apalutamide significantly improved overall survival in patients with non-metastatic castration-resistant prostate cancer

ASCO 2020: Apalutamide significantly improved overall survival in patients with non-metastatic castration...

More from ecancer